UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934

Artes Medical, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware		001-33205		33-0870808
(State or Other Jurisdiction		(Commission		(I.R.S. Employer
of Incorporation)		File Number)		Identification No.)

(Address of Principal Executive Offices, with zip code)

(Registrant’s telephone number, including area code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 1.02. Termination of a Material Definitive Agreement.

     Artes Medical, Inc. today announced that on November 21, 2008, the Company received written notice from Anika Therapeutics, Inc. terminating the Distribution Agreement between the Artes Medical, Inc. and Anika Therapeutics, Inc. The Distribution Agreement was entered into by the parties on July 7, 2008 for the distribution and sale of Elevess, a temporary dermal filler manufactured by Anika Therapeutics, Inc.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     On November 21, 2008, Mr. Christopher Reinhard resigned from his position as principal executive officer and an employee of Artes Medical, Inc.. Mr. Reinhard continues to serve on the Board of Directors of Artes Medical, Inc.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: November 24, 2008